Plasma levels of the chemokine CXCL12 are elevated in mice following acute cocaine exposure and decreased in human cocaine abusers during withdrawal. CXCL12 is also one of the few chemokines located in the brain and can modulate dopamine transmission through activation of its receptor CXCR4. To assess a role for the CXCL12/CXCR4 system in behavioral effects of cocaine, we tested the hypothesis that AMD 3100 (Plerixafor), a CXCR4 antagonist, would inhibit conditioned place preference (CPP) and locomotor activation produced by cocaine. Rats injected with cocaine (10 mg/kg) displayed CPP relative to saline-injected controls following 4 conditioning sessions. AMD 3100 (1, 2.5, 5 mg/kg) administered prior to cocaine conditioning reduced development of cocaine CPP. AMD 3100 (5 mg/kg) also inhibited expression of cocaine-induced CPP in a paradigm in which it was injected once (following cocaine conditioning and just prior to CPP testing). In addition, AMD 3100 (5, 10 mg/kg) pretreatment reduced locomotor activation produced by an acute cocaine injection (15 mg/kg) but did not affect basal locomotor activity relative to saline-injected controls. Repeated cocaine exposure produced a significant increase (1.49-fold) in CXCL12 mRNA expression in the ventral tegmental area (VTA). Our results suggest that the CXCL12/CXCR4 system in the brain reward circuit is impacted by cocaine exposure and influences behavioral effects related to the abuse liability of cocaine.
Introduction
Central functions of chemokines are not restricted to neuroinflammation and chemotaxis but extend to neuromodulatory actions on physiological circuits underlying central nervous system (CNS) diseases (Cui et al., 2014; Adler et al., 2005) . CXCL12, formerly known as stromal cell derived factor one alpha (SDF-1a), is one of the few chemokines found in the brain and is secreted by neuronal and non-neuronal populations (Banisadr et al., 2003; Tissir et al., 2004; Stumm et al., 2007; Guyon, 2014) . CXCL12 binds to and activates two receptors, CXCR4 and CXCR7, the former being the major receptor for CXCL12 in the brain that is expressed by astrocytes, microglia, and neurons (Bleul et al., 1996; Bajetto et al., 2001) . CXCR4 also has a commercially-available antagonist (AMD3100) available to probe its receptor mechanism. AMD3100 (Plerixafor) displays selectivity for CXCR4 (e.g. calcium flux assays revealed no interaction of AMD3100 with the chemokine receptors CXCR1 through CXCR3, or CCR1 through CCR9) (Hatse et al., 2002; Wilson et al., 2011) . AMD3100 is also FDA-approved as an immunostimulant to mobilize stem cells in cancer patients (Khan et al., 2007) ; therefore, human safety data would facilitate its clinical use for the treatment of addiction.
Chemokine systems are altered by cocaine exposure and can influence behavioral effects of cocaine. Plasma chemokine levels are reduced in cocaine abusers during withdrawal and elevated in mice following acute cocaine exposure (Araos et al., 2015) . The administration of CXCL12 intracerebroventricularly (icv) or into the ventral tegmental area (VTA) enhances locomotor activation produced by cocaine (Trecki and Unterwald, 2009) . CXCL12 injected into the substantia nigra enhances extracellular dopamine in the dorsal striatum in a CXCR4 receptor-dependent manner (Skrzydelski et al., 2007; Guyon, 2014) . Immunohistochemical data show that CXCR4 receptors are expressed by dopamine neurons in the substantia nigra (Banisadr et al., 2002) and GABAergic medium spiny neurons in the lateral shell of the nucleus accumbens (Trecki et al., 2010 ). Here, we tested the hypothesis that the CXCR4 receptor system influences rewarding and locomotor stimulant effects of cocaine.
